Cargando…

Cost-Effectiveness and Budget Impact Analyses of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia from the Singapore Healthcare System Perspective

PURPOSE: Children and young adults with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL) have poor survival due to ineffective therapy options. The newly approved chimeric antigen receptor T-cell (CAR-T) therapy, tisagenlecleucel, has demonstrated improved survival but at a high up-fr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xiao Jun, Wang, Yi-Ho, Ong, Matthew Jian Chun, Gkitzia, Christina, Soh, Shui Yen, Hwang, William Ying Khee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078873/ https://www.ncbi.nlm.nih.gov/pubmed/35535300 http://dx.doi.org/10.2147/CEOR.S355557

Ejemplares similares

Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia
por: Verneris, Michael R., et al.
Publicado: (2021)

CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
por: Vairy, Stephanie, et al.
Publicado: (2018)

Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma
por: Thudium Mueller, Karen, et al.
Publicado: (2021)

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
por: Laetsch, Theodore W., et al.
Publicado: (2023)

Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
por: v. Stackelberg, Arend, et al.
Publicado: (2023)

Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns
por: Barsan, Valentin, et al.
Publicado: (2023)

Tisagenlecleucel: The First CAR on the Highway to Remission for Acute Lymphoblastic Leukemia
por: Freyer, Craig W.
Publicado: (2018)

Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia
por: Moskop, Amy, et al.
Publicado: (2022)

Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital’s Perspective
por: Yang, Hongbo, et al.
Publicado: (2020)

Case report: Tisagenlecleucel for treatment of relapsed B- acute lymphoblastic leukemia in a patient with CHEK2 mutation
por: Ipe, Abraham, et al.
Publicado: (2023)

Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection
por: Hall, Erin M, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain
por: Ribera Santasusana, Josep Maria, et al.
Publicado: (2020)

Correction: Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection
Publicado: (2021)

Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
por: Salles, Gilles, et al.
Publicado: (2022)

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia
por: Pulsipher, Michael A., et al.
Publicado: (2022)

Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma
por: Iacoboni, Gloria, et al.
Publicado: (2021)

P1111: COMPARATIVE EFFICACY AND SAFETY OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
por: Dickinson, M., et al.
Publicado: (2022)

Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma
por: Maziarz, Richard T., et al.
Publicado: (2022)

Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia
por: Levine, John E, et al.
Publicado: (2021)

A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore
por: Ong, Jian Chun Matthew, et al.
Publicado: (2023)

Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date
por: Zavras, PD, et al.
Publicado: (2019)

Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma
por: Goto, Hideki, et al.
Publicado: (2020)

Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report
por: Fabrizio, Vanessa A., et al.
Publicado: (2022)

Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma
por: Jaeger, Ulrich, et al.
Publicado: (2022)

Cost-utility and value of information analysis of tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma in the Irish healthcare setting
por: Carey, Niamh, et al.
Publicado: (2023)

Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy
por: Zhao, Junmei, et al.
Publicado: (2015)

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
por: Bhojwani, Deepa, et al.
Publicado: (2018)

Inotuzumab Ozogamicin in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
por: Williams, Sherry, et al.
Publicado: (2018)

Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
por: DeAngelo, Daniel J., et al.
Publicado: (2020)

P1398: AXICABTAGENE CILOLEUCEL VERSUS TISAGENLECLEUCEL CAR-T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Gagelmann, Nico, et al.
Publicado: (2023)

Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia
por: Topp, M S, et al.
Publicado: (2018)

Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children
por: Xie, Jiao, et al.
Publicado: (2023)

Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia
por: Ribera, Josep-Maria, et al.
Publicado: (2015)

Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
por: Uy, Natalie, et al.
Publicado: (2018)

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
por: Bertamini, Luca, et al.
Publicado: (2018)

Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia
por: La Starza, Roberta, et al.
Publicado: (2019)

Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
por: Bhojwani, Deepa, et al.
Publicado: (2019)

Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia
por: Shimony, Shai, et al.
Publicado: (2022)

An observational study of Chinese adults with relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia
por: Ma, Jun, et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Tisagenlecleucel for the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain
por: Bastos-Oreiro, Mariana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tif8inadd5fnp629unkmh39rgh